Consumers Health Forum mistaken about ASMI’s advertising reform proposal for certain Pharmacist Only Medicines

23 January 2014

Return to Media Release Index

23 January 2014 - The Consumers Health Forum (CHF) has unfortunately missed a key element expressed in a proposal from the Australian Self-Medication Industry (ASMI) to lift current advertising restrictions on certain Pharmacist Only Medicines.

Contrary to CHF's media statement today, ASMI's proposal does not advocate for codeine-containing analgesics to be included in the advertising changes.

ASMI was explicit in exempting codeine-containing analgesics, as well as pseudoephedrine, from its proposal to introduce an alternative regulatory model for the advertising of Pharmacist Only Medicines.

Under ASMI's proposed model, the emphasis will be on creating consumer awareness about the condition and/or symptoms for a selection of Pharmacist Only medicines, and highlighting the importance of the role of the pharmacist in determining whether the product is appropriate for that consumer. Examples include Proton-pump inhibitors (PPIs) for the treatment of heartburn and cold sore treatments.

About ASMI: The Australian Self-Medication Industry (ASMI) is the peak body representing sponsors of non-prescription medicines - over-the-counter (OTC) and complementary medicines. Its members make up 85 per cent of the $4bn self care market. Membership totals 60 companies and ASMI members employ approximately 17,000 people with exports estimated at $600 million annually. ASMI's mission is to promote better health through responsible self care. This means ensuring that safe and effective self care products are readily available to all Australians at a reasonable cost. ASMI works to encourage responsible use by consumers and an increasing role for cost-effective self-medication products as part of the broad national health strategy.

For more information or to arrange a media interview, please contact:
Michelle Sollitt-Davis
PR Manager, Australian Self Medication Industry (ASMI)
M:0422 084 951 E: